Home / Technology / Altman's OpenAI Invests in His Own Brain Interface Startup
Altman's OpenAI Invests in His Own Brain Interface Startup
15 Jan
Summary
- OpenAI invested in Sam Altman's brain-computer interface startup Merge Labs.
- Merge Labs aims to connect neurons non-invasively using molecules and ultrasound.
- This investment intensifies the BCI competition with Elon Musk's Neuralink.
OpenAI has significantly deepened its involvement in the burgeoning brain-computer interface (BCI) field by investing in Merge Labs, a startup founded by its own CEO, Sam Altman. Merge Labs, which emerged from stealth with a $250 million seed round at an $850 million valuation, focuses on "bridging biological and artificial intelligence" non-invasively. The company intends to develop novel technologies that interface with neurons using molecules and ultrasound, rather than invasive electrodes.
This strategic investment intensifies the high-profile competition in the BCI sector, particularly between Altman and Elon Musk, whose Neuralink is developing implantable chips requiring surgery. OpenAI stated its participation stems from the belief that BCIs offer a new frontier for seamless human-AI interaction. The collaboration between OpenAI and Merge Labs is expected to accelerate progress in bioengineering and neuroscience through shared scientific foundation models and AI operating systems.
The investment in Merge Labs, a company where Altman holds an ownership stake, highlights a circular deal structure that could potentially drive more users to OpenAI's ecosystem. This aligns with Altman's long-held vision of a "Merge" between humans and machines, which he believes is humanity's best-case scenario for coexisting with superintelligence.
